[Prophylaxis against adverse effects of chemotherapy for HIV positive patients]

Since the era of HAART cancers in patients infected with HIV are responsible for more than 10% of the residual deaths. One of the more important goal to achieve a better prognosis in these patients, is to prevent the adverse drug events. Unfortunately, these adverse events are frequent because of the chemotherapy-antiretrovirals drug-drug interactions, poor physiologic status, hematologic toxicity enhanced by HIV dysmyelopoiesis and infectious complications. The risk is to be unable to pursue the entire therapeutic program. This paper describes how a narrow collaboration between the oncologist and the specialist of HIV disease could prevent such events.